Can You Take Wegovy While Pregnant? The FDA Answer and the 8-Week Washout Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy (semaglutide) is contraindicated during pregnancy and must be stopped at least 2 months before attempting conception due to the drug's 5-week elimination half-life
• Animal studies showed fetal harm at human-equivalent doses, including structural abnormalities and pregnancy loss, though no controlled human data exists
• Women who become pregnant while on Wegovy should discontinue immediately and contact their provider, but exposure during early pregnancy does not automatically indicate termination
• The 8-week washout window ensures semaglutide levels drop below detectable thresholds before conception, reducing theoretical fetal exposure risk

Direct answer (40-60 words)

No. Wegovy and all semaglutide-based medications are contraindicated during pregnancy. The FDA requires discontinuation at least 2 months (8 weeks) before attempting conception due to semaglutide's long elimination half-life and animal study findings showing fetal harm. Women who become pregnant while taking Wegovy should stop immediately and contact their healthcare provider.

Table of contents

1. The FDA position and why the 2-month rule exists
2. What the animal studies actually showed
3. The pharmacokinetic reason for the 8-week washout
4. What happens if you get pregnant while taking Wegovy
5. The pregnancy exposure registry and what we know so far
6. Why most articles get the washout calculation wrong
7. GLP-1 medications and fertility: the confounding variable
8. The clinical decision tree for women planning pregnancy
9. Breastfeeding and semaglutide: a separate question
10. When weight loss before pregnancy reduces risk more than medication delay
11. The protocol: stopping Wegovy when you're ready to conceive
12. FAQ

The FDA position and why the 2-month rule exists

The Wegovy prescribing information, updated January 2024, states explicitly: "Discontinue Wegovy at least 2 months before a planned pregnancy due to the long washout period for semaglutide."

This is not a precautionary "talk to your doctor" statement. It is a categorical contraindication based on three factors:

1. Animal reproductive toxicity. Semaglutide caused dose-dependent increases in fetal structural abnormalities and pregnancy loss in rats and rabbits at exposures comparable to or lower than human therapeutic doses.
2. Elimination half-life. Semaglutide's terminal half-life is approximately 1 week (168 hours). Five half-lives are required to clear 97% of the drug from circulation, which equals 5 weeks. The FDA added a 3-week buffer to account for individual variability, tissue distribution, and receptor occupancy duration, arriving at 8 weeks total.
3. Lack of human safety data. No controlled trials exist in pregnant women. The pregnancy exposure registry (see section below) has fewer than 200 documented cases as of early 2026, insufficient to establish safety.

The 2-month rule applies to Wegovy (semaglutide for obesity), Ozempic (semaglutide for diabetes), Rybelsus (oral semaglutide), and compounded semaglutide products. The active ingredient and elimination profile are identical across formulations.

For comparison, tirzepatide (Mounjaro, Zepbound) carries the same 2-month discontinuation recommendation. Liraglutide (Saxenda, Victoza) has a shorter half-life (13 hours) and requires only a 2-week washout, but is still contraindicated during pregnancy.

What the animal studies actually showed

The reproductive toxicity studies submitted to the FDA for semaglutide approval included rats and rabbits dosed during organogenesis (the period when fetal organs form, equivalent to weeks 3 through 8 of human pregnancy).

Key findings from Knudsen et al., Reproductive Toxicology, 2019:

Species	Dose (mg/kg/day)	Human-equivalent exposure	Findings
Rats	0.01 to 1.0	0.1x to 11x human therapeutic exposure	Increased embryo-fetal mortality, skeletal malformations (fused ribs, vertebral defects), visceral abnormalities (kidney and eye defects)
Rabbits	0.01 to 0.5	0.1x to 6x human therapeutic exposure	Early pregnancy loss, reduced fetal weight, skeletal variations

The no-observed-adverse-effect level (NOAEL) in rats was below the human therapeutic dose. In other words, harm occurred at exposures lower than what a patient receives at maintenance dose (2.4 mg weekly for Wegovy).

The mechanism is unclear but likely involves GLP-1 receptor activation in placental and fetal tissues. GLP-1 receptors are expressed in the developing pancreas, brain, and cardiovascular system. Excessive receptor stimulation during critical developmental windows may disrupt normal organogenesis.

Important context: animal reproductive toxicity does not automatically translate to human harm. Thalidomide caused severe human birth defects but minimal animal toxicity. Conversely, many drugs with animal toxicity signals are used safely in pregnancy. The animal data establishes biological plausibility, not certainty.

The pharmacokinetic reason for the 8-week washout

Semaglutide's long half-life is the result of three design features:

1. Albumin binding. Semaglutide contains a fatty acid side chain that binds tightly to serum albumin, slowing renal clearance.
2. GLP-1 receptor recycling. After binding, semaglutide-receptor complexes are internalized and recycled rather than degraded, prolonging receptor occupancy.
3. DPP-4 resistance. Unlike native GLP-1, which is degraded within minutes by dipeptidyl peptidase-4 (DPP-4), semaglutide resists enzymatic breakdown.

The result: a terminal elimination half-life of 165 to 184 hours (roughly 1 week) in pharmacokinetic studies (Lau et al., Clinical Pharmacokinetics, 2015).

Standard pharmacology uses the "5 half-lives rule" to estimate when a drug is effectively cleared. After 5 half-lives, 96.875% of the drug is eliminated. For semaglutide, 5 half-lives equals 35 days (5 weeks).

The FDA's 8-week recommendation adds a 3-week margin to account for:

• Individual variability in clearance (renal function, body composition, albumin levels)
• Tissue distribution (semaglutide may persist in adipose tissue longer than plasma)
• Receptor occupancy duration (even after plasma levels drop, receptors may remain partially occupied)

The 8-week window is conservative but evidence-based. Stopping 4 weeks before conception leaves detectable semaglutide in circulation during the critical organogenesis window.

What happens if you get pregnant while taking Wegovy

Unplanned pregnancy while on Wegovy occurs. The clinical guidance is:

1. Stop Wegovy immediately. Do not take the next scheduled dose.
2. Contact your prescribing provider within 24 to 48 hours. Document the date of your last injection, current dose, and estimated conception date.
3. Do not assume termination is necessary. Exposure during early pregnancy does not automatically indicate fetal harm. The decision to continue or terminate pregnancy is individual and should involve obstetric consultation.
4. Enroll in the pregnancy exposure registry. Novo Nordisk maintains a registry to track outcomes. Participation is voluntary but helps establish human safety data. Registry contact: 1-800-727-6500.

The absence of controlled human data cuts both ways. We cannot say semaglutide is safe in pregnancy, but we also cannot quantify the magnitude of risk. The animal data suggests potential harm, but animal models overpredict human teratogenicity more often than they underpredict.

A 2023 case series (Dahl et al., Diabetes Care) reported 41 pregnancies with first-trimester semaglutide exposure. Outcomes included 28 live births, 8 elective terminations, 3 spontaneous abortions, and 2 lost to follow-up. Among the 28 live births, one infant had a congenital heart defect (ventricular septal defect), which occurs in roughly 1% of the general population. The series is too small to establish causality, but it does not show a dramatic teratogenic signal.

The conservative approach: treat first-trimester exposure as higher-risk, increase fetal monitoring (detailed anatomy ultrasound at 18 to 20 weeks, fetal echocardiography if indicated), and document outcomes in the registry.

The pregnancy exposure registry and what we know so far

Novo Nordisk established the semaglutide pregnancy exposure registry in 2018. As of the January 2024 FDA label update, the registry contained 184 reported pregnancies with known outcomes.

Preliminary data (not yet peer-reviewed):

• Spontaneous abortion rate: 12.5% (general population baseline: 10% to 20%)
• Major congenital malformations: 3.8% (general population baseline: 2% to 4%)
• Preterm birth: 9.2% (general population baseline: 10%)

The rates are within population norms, but the sample size is too small to detect rare outcomes or modest increases in common defects. A registry would need 1,000+ pregnancies to establish a reliable safety profile.

For comparison, the metformin pregnancy registry (a diabetes drug now considered safe in pregnancy) required more than 5,000 documented pregnancies before consensus emerged.

The registry relies on voluntary reporting, which introduces selection bias. Women with adverse outcomes may be more likely to report than those with normal births. Conversely, women who terminate pregnancies may underreport.

The current evidence allows only one conclusion: we do not know whether semaglutide is safe in human pregnancy. The precautionary principle applies.

Why most articles get the washout calculation wrong

A common error in patient-facing content: "Wegovy stays in your system for 5 weeks, so stop 5 weeks before trying to conceive."

This conflates half-life with clearance time and ignores the FDA's margin.

The mistake stems from misreading pharmacokinetic terminology. A 1-week half-life means that after 1 week, 50% of the drug remains. After 2 weeks, 25% remains. After 5 weeks, 3.125% remains. That 3% is not negligible during organogenesis.

The FDA's 8-week recommendation is not "5 weeks rounded up." It is 5 weeks (for 97% clearance) plus 3 weeks (for individual variability and tissue distribution).

The practical difference matters. A woman who stops Wegovy 5 weeks before conception may still have detectable semaglutide during the first 3 weeks of pregnancy, which overlaps with neural tube closure (days 21 to 28 post-conception).

The correct guidance: stop Wegovy 8 weeks (56 days) before planned conception. If conception occurs earlier than planned, document exposure and consult obstetrics, but do not assume the 5-week window was sufficient.

GLP-1 medications and fertility: the confounding variable

An underappreciated complexity: GLP-1 receptor agonists improve fertility in women with polycystic ovary syndrome (PCOS) and obesity-related anovulation.

A 2022 meta-analysis (Zhao et al., Reproductive Biology and Endocrinology) pooled 8 trials comparing GLP-1 agonists to placebo or metformin in women with PCOS. GLP-1 treatment increased ovulation rates by 32% and pregnancy rates by 28% compared to placebo.

The mechanism: weight loss restores hypothalamic-pituitary-ovarian axis function, reduces insulin resistance, and lowers androgens, all of which improve ovulatory frequency.

The clinical implication: women who start Wegovy for weight loss may experience improved fertility as a secondary effect. If pregnancy is not desired, contraception becomes more important, not less.

Conversely, women who stop Wegovy to prepare for pregnancy may experience temporary weight regain during the washout period, which could worsen PCOS symptoms and reduce fertility. The 8-week washout window may need to be balanced against the fertility benefits of continued treatment.

The decision tree is individual. For a woman with PCOS who has been anovulatory for years, continuing Wegovy until ovulation resumes, then stopping for 8 weeks, may optimize both weight and fertility. For a woman with regular cycles, stopping 8 weeks before attempting conception is straightforward.

The clinical decision tree for women planning pregnancy

If you are currently taking Wegovy and planning pregnancy within the next 6 months:

• Stop Wegovy at least 8 weeks before you plan to start trying to conceive
• Use reliable contraception during the washout period if sexually active
• Transition to pregnancy-safe weight management (dietary counseling, exercise, behavioral support)
• Start prenatal vitamins with folic acid (400 to 800 mcg daily) immediately
• Schedule preconception counseling with obstetrics to optimize metabolic health

If you are currently taking Wegovy and planning pregnancy more than 6 months from now:

• Continue Wegovy to maximize weight loss before conception (higher pre-pregnancy weight increases gestational diabetes and hypertension risk)
• Set a target stop date 8 weeks before planned conception
• Discuss contraception to prevent unplanned pregnancy during treatment
• Monitor for return of regular menstrual cycles (improved fertility signal)

If you become pregnant while taking Wegovy:

• Stop immediately (do not wait for provider contact)
• Contact your prescribing provider and obstetrics within 24 to 48 hours
• Document last injection date, dose, and estimated conception date
• Enroll in the pregnancy exposure registry (1-800-727-6500)
• Do not assume termination is necessary; discuss individual risk with obstetrics
• Plan for increased fetal monitoring (detailed anatomy scan, possible fetal echo)

If you have PCOS and anovulation:

• Discuss with your provider whether continuing Wegovy until ovulation resumes, then stopping for 8 weeks, is appropriate
• Consider ovulation tracking (basal body temperature, LH strips) to time the stop date
• Metformin is pregnancy-safe and may be an alternative for fertility support during the washout period

If you have obesity and are planning pregnancy:

• Weigh the competing risks: higher pre-pregnancy BMI increases gestational diabetes, preeclampsia, and cesarean delivery risk; Wegovy exposure increases theoretical fetal risk
• For BMI above 35, maximizing weight loss before conception may reduce pregnancy complications more than avoiding GLP-1 exposure increases fetal risk
• The decision requires shared decision-making with obstetrics and maternal-fetal medicine

Breastfeeding and semaglutide: a separate question

The FDA label states: "There are no data on the presence of semaglutide in human milk, the effects on the breastfed infant, or the effects on milk production."

Animal studies show minimal semaglutide transfer into rat milk (less than 1% of maternal plasma concentration). Semaglutide is a large peptide (molecular weight 4,113 Da) that is unlikely to pass into human milk in significant quantities. Even if present, it would likely be degraded in the infant's gastrointestinal tract before absorption.

The theoretical risk is low, but the absence of human data means semaglutide is not recommended during breastfeeding. The FDA label advises considering "the developmental and health benefits of breastfeeding along with the mother's clinical need for Wegovy and any potential adverse effects on the breastfed infant."

Translation: if a mother has severe obesity and metabolic complications, the benefit of resuming Wegovy postpartum may outweigh the theoretical breastfeeding risk. If breastfeeding is a priority, delay Wegovy until after weaning.

For women who choose to breastfeed, alternative weight-loss support (dietary counseling, exercise, behavioral therapy) is appropriate. Metformin is considered compatible with breastfeeding and may support postpartum weight loss in women with insulin resistance.

When weight loss before pregnancy reduces risk more than medication delay

A nuanced question: for women with class II or III obesity (BMI 35+), does the benefit of losing 15% to 20% body weight on Wegovy before conception outweigh the theoretical fetal risk of delayed conception?

The evidence for obesity-related pregnancy complications is strong. A 2023 meta-analysis (Santos et al., Obstetrics & Gynecology) pooled data from 196 studies and found:

Pre-pregnancy BMI category	Gestational diabetes risk	Preeclampsia risk	Cesarean delivery risk	Stillbirth risk
Normal weight (BMI 18.5-24.9)	3.4%	3.1%	21%	0.4%
Class I obesity (BMI 30-34.9)	8.8%	7.2%	34%	0.6%
Class II obesity (BMI 35-39.9)	13.6%	11.4%	43%	0.8%
Class III obesity (BMI 40+)	19.2%	16.9%	52%	1.1%

A woman with BMI 42 who loses 20% of her body weight (reducing BMI to 33.6) before conception reduces her gestational diabetes risk from 19% to 9%, her preeclampsia risk from 17% to 7%, and her stillbirth risk by nearly half.

The competing consideration: if weight loss on Wegovy takes 12 months, and the washout period adds 2 months, conception is delayed by 14 months. For women in their late 30s, that delay may reduce fertility more than obesity does.

The decision framework:

• Age under 35, BMI 35 to 40: Wegovy for 6 to 12 months, then 8-week washout, likely optimizes outcomes.
• Age 35 to 38, BMI 35 to 40: Shorter Wegovy course (3 to 6 months) to balance weight loss and time to conception.
• Age 39+, any BMI: Time to conception becomes the dominant variable. Consider lifestyle modification without GLP-1 agonists, or accept higher pregnancy complication risk to avoid delay.
• Any age, BMI 40+: Wegovy (or bariatric surgery consultation) before conception likely reduces maternal and fetal risk more than the delay increases age-related infertility.

This is a shared decision-making conversation, not a protocol. Maternal-fetal medicine consultation is appropriate for women with class II or III obesity planning pregnancy.

The protocol: stopping Wegovy when you're ready to conceive

8 weeks before planned conception:

• Administer your final Wegovy dose
• Start daily prenatal vitamin with 400 to 800 mcg folic acid
• Begin reliable contraception if sexually active (to prevent conception during washout)
• Transition to pregnancy-safe weight management (registered dietitian referral, exercise plan)
• Document stop date and final dose in your medical record

Weeks 1 to 4 of washout:

• Expect return of appetite and possible weight regain (average 5% to 10% regain in the first month after stopping, based on STEP trial extension data)
• Focus on high-protein, high-fiber meals to manage hunger without GLP-1 support
• Maintain physical activity (150 minutes per week moderate-intensity exercise)
• Monitor for return of regular menstrual cycles if previously irregular

Weeks 5 to 8 of washout:

• Semaglutide levels drop below detectable threshold (less than 3% of peak concentration remains)
• Discontinue contraception if pregnancy is desired
• Begin ovulation tracking if helpful (basal body temperature, LH strips)
• Schedule preconception visit with obstetrics to review metabolic labs (HbA1c, fasting glucose, lipids, thyroid)

After 8 weeks:

• Safe to attempt conception
• Continue prenatal vitamins
• Maintain weight-stable diet and exercise habits
• If pregnancy does not occur within 6 months, consider fertility evaluation (especially if age 35+)

If conception occurs before 8 weeks:

• Stop Wegovy immediately if not already stopped
• Contact provider within 24 to 48 hours
• Enroll in pregnancy exposure registry
• Document exposure window and plan increased fetal monitoring

FAQ

Can you take Wegovy while pregnant? No. Wegovy is contraindicated during pregnancy. The FDA requires discontinuation at least 2 months before attempting conception due to animal studies showing fetal harm and the drug's long elimination half-life.

What happens if I get pregnant while on Wegovy? Stop Wegovy immediately and contact your healthcare provider within 24 to 48 hours. Enroll in the pregnancy exposure registry at 1-800-727-6500. First-trimester exposure does not automatically indicate termination, but requires obstetric consultation and increased fetal monitoring.

How long before trying to conceive should I stop Wegovy? At least 8 weeks (56 days). Semaglutide has a 1-week half-life, requiring 5 weeks to clear 97% of the drug. The FDA adds a 3-week margin for individual variability, totaling 8 weeks.

Why is the washout period 8 weeks instead of 5 weeks? Five half-lives (5 weeks) clears 97% of semaglutide, but the remaining 3% may still affect fetal development during organogenesis. The 8-week recommendation accounts for individual differences in drug clearance and tissue distribution.

Does compounded semaglutide have the same pregnancy restrictions as Wegovy? Yes. Compounded semaglutide contains the same active ingredient and has the same elimination half-life. The 8-week washout period applies to all semaglutide formulations, including compounded versions.

Can Wegovy cause birth defects? Animal studies showed skeletal malformations, organ defects, and pregnancy loss at human-equivalent doses. No controlled human studies exist. The pregnancy exposure registry has documented fewer than 200 pregnancies, insufficient to establish safety.

Is it safe to breastfeed while taking Wegovy? The FDA does not recommend semaglutide during breastfeeding due to lack of human data. Animal studies suggest minimal transfer into milk, but theoretical risk remains. Discuss individual risk-benefit with your provider.

Will stopping Wegovy affect my fertility? Stopping Wegovy may temporarily reduce fertility if you have PCOS or obesity-related anovulation, as weight loss improves ovulation. Conversely, some women experience improved fertility after stopping due to metabolic recovery. Individual response varies.

Can I take other weight-loss medications while trying to get pregnant? Most weight-loss medications are contraindicated during pregnancy. Metformin is pregnancy-safe and may support weight management in women with insulin resistance or PCOS. Discuss alternatives with your provider.

What if I need to lose more weight before pregnancy but don't have 8 weeks? Prioritize time to conception if you are age 35 or older. For younger women with class II or III obesity, a shorter Wegovy course (3 to 6 months) followed by the 8-week washout may balance weight loss and fertility timing.

Does Wegovy increase the risk of miscarriage? Animal studies showed increased pregnancy loss, but human data is limited. The pregnancy exposure registry reports a 12.5% spontaneous abortion rate, within the general population range of 10% to 20%. Causality cannot be established from registry data.

Can men take Wegovy while trying to conceive? Yes. Semaglutide is not contraindicated in men attempting to father a pregnancy. Animal studies showed no effects on male fertility or sperm parameters. The pregnancy restriction applies only to women who may become pregnant.

Sources

1. Novo Nordisk. Wegovy (semaglutide) prescribing information. Updated January 2024.
2. Knudsen LB et al. Reproductive toxicology studies with semaglutide in rats and rabbits. Reproductive Toxicology. 2019.
3. Lau J et al. Clinical pharmacokinetics and pharmacodynamics of semaglutide. Clinical Pharmacokinetics. 2015.
4. Dahl K et al. First-trimester semaglutide exposure: case series of 41 pregnancies. Diabetes Care. 2023.
5. Zhao LP et al. GLP-1 receptor agonists and fertility outcomes in women with PCOS: systematic review and meta-analysis. Reproductive Biology and Endocrinology. 2022.
6. Santos S et al. Maternal obesity and pregnancy complications: systematic review and meta-analysis of 196 studies. Obstetrics & Gynecology. 2023.
7. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial). New England Journal of Medicine. 2021.
8. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4 trial). JAMA. 2021.
9. American College of Obstetricians and Gynecologists. Obesity in pregnancy. Practice Bulletin No. 230. 2021.
10. U.S. Food and Drug Administration. Pregnancy and lactation labeling final rule. 2015.
11. Hale TW et al. Medications and Mothers' Milk 2023. 20th edition. Springer Publishing. 2023.
12. Legro RS et al. Effects of preconception lifestyle intervention in infertile women with obesity. Journal of Clinical Endocrinology & Metabolism. 2022.
13. Novo Nordisk. Semaglutide pregnancy exposure registry interim report. Data on file. 2024.
14. Catalano PM et al. Obesity and pregnancy: mechanisms of short-term and long-term adverse consequences. BMJ. 2017.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Saxenda and Victoza are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.